Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precipio Inc PRPO

Healthcare
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through... see more

Recent & Breaking News (NDAQ:PRPO)

Precipio Announces Q3-2024 Shareholder Update Call

GlobeNewswire November 6, 2024

Precipio Expands Bloodhound(TM) MPN Panel by Adding CALR Mutation Subtyping

GlobeNewswire October 8, 2024

Precipio Announces Employee Stock Option Plan Repricing

GlobeNewswire September 6, 2024

Precipio Announces Q2-2024 Shareholder Update Call

GlobeNewswire August 15, 2024

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

GlobeNewswire July 25, 2024

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

GlobeNewswire July 17, 2024

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

GlobeNewswire June 13, 2024

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

GlobeNewswire June 12, 2024

Precipio Provides Status Update on Current Business Matters

GlobeNewswire June 12, 2024

Precipio Secures a short-term $500K Credit Facility

GlobeNewswire May 6, 2024

Precipio Announces Year end 2023 Shareholder Update Call

GlobeNewswire March 25, 2024

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

GlobeNewswire February 13, 2024

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

GlobeNewswire February 6, 2024

Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

GlobeNewswire January 23, 2024

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

GlobeNewswire January 17, 2024

Precipio Announces Christina Valauri joins the Board of Directors

GlobeNewswire January 2, 2024

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

GlobeNewswire December 14, 2023

Precipio Announces Q3-2023 Shareholder Update Call

GlobeNewswire November 16, 2023

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

GlobeNewswire October 18, 2023

Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

GlobeNewswire October 3, 2023